Advanced Vaccine Design Strategies against SARS-CoV-2 and Emerging Variants

Jianzhong Zhang, Yutian Xia, Xuan Liu, Gang LiuBioengineering 2023 · DOI

TL;DR

This review explores advanced vaccine design strategies against SARS-CoV-2 and its emerging variants, highlighting how cutting-edge biotechnology is crucial for developing effective and broad-spectrum vaccines. It discusses structure-guided design, T-cell-based approaches, respiratory mucosal delivery, and nanotechnologies as key avenues for overcoming current vaccine limitations and future pandemic preparedness.

What Problem Does This Paper Address?

The COVID-19 pandemic has underscored the critical need for effective vaccines to combat infectious diseases. While existing vaccines have shown success in preventing severe illness, the emergence of new SARS-CoV-2 variants poses a significant challenge due to their increased transmissibility and potential to evade immune responses. This necessitates the development of novel vaccine strategies that can provide more robust and durable protection against current and future viral strains. Traditional vaccine approaches may not be sufficient to address these evolving threats, highlighting a gap in our ability to rapidly and effectively respond to emerging infectious diseases.

Methods

This paper is a review, synthesizing existing research on advanced vaccine design strategies. It doesn't introduce new experimental methods but rather categorizes and discusses the principles behind several key approaches:

  • Structure-Guided Vaccine Design: This strategy leverages detailed knowledge of the SARS-CoV-2 spike protein's structure, particularly its metastable prefusion conformation. By stabilizing this conformation, researchers aim to expose key neutralizing epitopes more effectively to the immune system. Techniques like proline substitutions (e.g., S-2P, HexaPro) and the use of trimerization tags (e.g., Trimer-Tag) are employed to achieve this.
  • T-Cell-Based Vaccines: Recognizing that antibodies alone may not be sufficient, this approach focuses on stimulating T-cell responses, particularly CD8+ T cells, which are crucial for clearing infected cells. This strategy aims to provide a more durable and cross-reactive immunity, especially against variants.
  • Respiratory Mucosal Delivery: Instead of traditional intramuscular injections, this method explores delivering vaccines directly to the respiratory tract, the primary site of SARS-CoV-2 entry. The goal is to elicit local mucosal immunity (e.g., IgA) and resident memory T cells, offering a first line of defense against infection and transmission.
  • Nanotechnologies: This approach utilizes nanoparticles as platforms to deliver antigens. Nanoparticles can enhance antigen presentation, improve stability, and allow for the display of multiple antigens (multivalent display) on a single particle. This is particularly relevant for creating mosaic nanoparticle vaccines that can present antigens from various SARS-CoV-2 variants to induce broader immune responses.

Datasets

Not discussed in the paper. This is a review article summarizing existing research and technologies, not presenting new experimental data or benchmarks.

Key Insights and Ideas

  • Beyond Antibodies: The paper emphasizes that while neutralizing antibodies are important, T-cell responses are crucial for long-term immunity and clearing infected cells, especially in the face of viral evolution.
  • Targeting the Prefusion Spike: Stabilizing the spike protein in its prefusion conformation is a key strategy for eliciting more effective neutralizing antibodies, as this conformation exposes critical epitopes.
  • The Power of Nanoparticles: Nanoparticle platforms offer a versatile way to present antigens, enabling the co-display of multiple variants (mosaic vaccines) to potentially overcome immune escape by emerging strains.
  • Local Immunity Matters: Delivering vaccines directly to the respiratory tract via mucosal routes could provide a more effective initial defense against airborne viruses like SARS-CoV-2.
  • Rational Design is Key: The shift from empirical vaccine development to rational, structure-based design is accelerating progress and improving vaccine efficacy.

Key Results

As this is a review, specific quantitative results are drawn from the studies discussed. The paper highlights:

  • mRNA Vaccines: mRNA vaccines (e.g., Pfizer-BioNTech, Moderna) have shown high efficacy (up to 95%) in clinical trials against the original SARS-CoV-2 strain.
  • Structure-Guided Success: Strategies like S-2P and HexaPro have demonstrated improved antigen stability and yield, leading to promising vaccine candidates.
  • T-Cell Preservation: T-cell responses induced by vaccines are shown to be more preserved against emerging variants compared to B-cell responses, suggesting their importance for broader protection. For instance, T-cell reactivity at 6 months post-vaccination was reported to be around 90% for CD4+ and 87% for CD8+ T cells, with good preservation against Omicron.
  • Mosaic Nanoparticles: These vaccines have shown potential in preclinical studies to elicit cross-reactive immune responses against various SARS-CoV-2 variants.

Limitations and Future Work

The authors acknowledge several challenges and areas for future research:

  • Waning Immunity: The duration of vaccine-induced immunity is a concern, as waning immunity can lead to rapid transmission and breakthrough infections. Heterologous prime-boost strategies are being explored to extend protection.
  • Thermo-Sensitivity: Many current vaccines require cold chain storage, complicating distribution. Developing thermo-stable vaccines is crucial for equitable global access.
  • Individual Differences: Factors like gender and age can influence vaccine-induced immunity, necessitating further investigation for personalized vaccine design.
  • Adjuvant Development: Novel and affordable adjuvants are needed to enhance vaccine efficacy and potentially reduce antigen dosage.
  • Manufacturing and Cost-Effectiveness: For nanoparticle vaccines, challenges remain in achieving large-scale, sustainable, and cost-effective manufacturing.
  • Long-Term Efficacy: Continued research is needed to understand how long immune responses will be maintained and to develop updated vaccines as new variants emerge.

Summary updated

Abstract

Vaccination is the most cost-effective means in the fight against infectious diseases. Various kinds of vaccines have been developed since the outbreak of COVID-19, some of which have been approved for clinical application. Though vaccines available achieved partial success in protecting vaccinated subjects from infection or hospitalization, numerous efforts are still needed to end the global pandemic, especially in the case of emerging new variants. Safe and efficient vaccines are the key elements to stop the pandemic from attacking the world now; novel and evolving vaccine technologies are urged in the course of fighting (re)-emerging infectious diseases. Advances in biotechnology offered the progress of vaccinology in the past few years, and lots of innovative approaches have been applied to the vaccine design during the ongoing pandemic. In this review, we summarize the state-of-the-art vaccine strategies involved in controlling the transmission of SARS-CoV-2 and its variants. In addition, challenges and future directions for rational vaccine design are discussed.
BibTeX
@inproceedings{zhang2023advanced,
  author = {Jianzhong Zhang and Yutian Xia and Xuan Liu and Gang Liu},
  title = {{Advanced Vaccine Design Strategies against SARS-CoV-2 and Emerging Variants}},
  booktitle = {Bioengineering},
  year = {2023},
  doi = {10.3390/bioengineering10020148},
}
Figure